Doctors are aiming radiation beams at arthritic knees, and the results suggest this unorthodox approach might spare some patients from pills or surgery.
A randomized trial in South Korea found that a single course of low-dose radiation therapy reduced pain and improved function in people with mild to moderate knee osteoarthritis, offering what researchers call a “moderate intervention” between medications and joint replacement.
The treatment sounds alarming at first. Radiation for a bad knee? But the doses involved are tiny. Patients received just 3 gray units of radiation over six sessions, less than 5% of what’s used in cancer treatment. The radiation targets joints positioned away from vital organs, and researchers reported zero side effects related to the therapy itself.
What makes this study unusual is its placebo control group. In a field notorious for strong placebo responses, 114 participants were randomly assigned to receive either a very low dose (0.3 Gy), a low dose (3 Gy), or simulated treatment where the machine was turned on but delivered nothing. Nobody knew which group they were in.
The Numbers Tell the Story
After four months, 70% of patients receiving the 3 Gy dose met criteria for meaningful improvement in pain, physical function, or overall condition. The placebo group wasn’t far behind at 42%, but the difference was statistically significant. The ultra-low 0.3 Gy dose performed no better than fake treatment, suggesting there’s a threshold effect at work.
There’s a clinical need for moderate interventions between weak pain medications and aggressive surgery, and we think radiation may be a suitable option for those patients especially when drugs and injections are poorly tolerated.
Byoung Hyuck Kim, the trial’s principal investigator and assistant professor at Seoul National University College of Medicine, presented the findings at the American Society for Radiation Oncology’s annual meeting in San Francisco. He emphasized that the study design minimized confounding factors. Participants were restricted to acetaminophen for pain relief during the four-month follow-up period, no stronger drugs allowed.
That restriction matters. Previous studies permitted NSAIDs or opioids, which could mask radiation’s effects. By keeping analgesics minimal, the Korean team could more confidently attribute improvements to the radiation itself rather than pharmaceutical interventions.
Old Treatment, New Evidence
